Company intelligence / Profile preview

Alzamend Neuro

Atlanta, Georgia, United Statesalzamend.com ↗

Ownership: Public · ALZN
Development stage: Phase 2

Overview

Alzamend has completed a Phase IIA multiple ascending dose study for AL001 in patients with Alzheimer's disease, identifying a maximum tolerated dose that likely won't require therapeutic drug monitoring. The company is planning multiple Phase II trials for AL001 starting in Q2 2025, with the first in healthy subjects at Massachusetts General Hospital. For ALZN002, they received FDA clearance for a Phase I/IIA trial in October 2022 and initiated the trial in March 2023.

Therapeutic areas: PsychiatryNeurology
Modalities: Ionic cocrystal technology (lithium delivery)Cell-based therapeutic vaccine
Industry: Biotech

Drug pipeline

4 assets

AL001

3 more assets in the full pipeline.

Request access →

Partnerships

Massachusetts General Hospital (contract research organization)

Financials

Market cap: $6.5M
Total revenue: $0
Enterprise value: $-1.1M

Beyond the preview

Go deeper on Alzamend Neuro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alzamend Neuro.

Explore the full profile